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Abstract. More than a century after the discovery of Plasmodium spp. parasites, the pathogenesis of severe malaria is
still not well understood. The majority of malaria cases are caused by Plasmodium falciparum and Plasmodium vivax,
which differ in virulence, red blood cell tropism, cytoadhesion of infected erythrocytes, and dormant liver hypnozoite
stages. Cerebral malaria coma is one of the most severe manifestations of P. falciparum infection. Insights into its complex
pathophysiology are emerging through a combination of autopsy, neuroimaging, parasite binding, and endothelial charac-
terizations. Nevertheless, important questions remain regarding why some patients develop life-threatening conditions
while the majority of P. falciparum-infected individuals do not, and why clinical presentations differ between children and
adults. For P. vivax, there is renewed recognition of severe malaria, but an understanding of the factors influencing
disease severity is limited and remains an important research topic. Shedding light on the underlying disease mechanisms
will be necessary to implement effective diagnostic tools for identifying and classifying severe malaria syndromes and
developing new therapeutic approaches for severe disease. This review highlights progress and outstanding questions
in severe malaria pathophysiology and summarizes key areas of pathogenesis research within the International Centers
of Excellence for Malaria Research program.
INTRODUCTION
Malaria is a major global infectious disease caused by para-
sitic protozoans of the genus Plasmodium. Of the five Plasmo-
dium species that infect humans, Plasmodium falciparum and
Plasmodium vivax cause themajority of cases, andP. falciparum
is the most virulent and responsible for the majority of deaths.1
Despite recent reductions in the overall malaria case incidence,
malaria remains a leading cause of morbidity and mortality
in the developing world. In 2012, there were an estimated
207 million cases of malaria and over 600,000 deaths.1 The
majority of malaria deaths (90%) occur in children in Africa,
where falciparum malaria accounts for as many as one in six
childhood deaths and is the biggest killer of African children
between the ages of 1 and 4 years.2,3 Outside Africa, there
are a variety of transmission settings where P. falciparum,
P. vivax, or both are present. In lower transmission settings in
South America, India, and southeast Asia, adult populations
are at higher risk for severe malaria.
Malaria is a complex disease, and the spectrum of disease
manifestations differs between children and adults.4 Symptoms
can range from none, in individuals with asymptomatic para-
sitemia, to mild, in patients with undifferentiated fever, to
severe, in patients with life-threatening anemia, metabolic aci-
dosis, cerebral malaria (CM), and multiorgan system involve-
ment.5 Only a small minority of infections, less than 1–2%, leads
to severe malaria.6 Because pathogenetic mechanisms are com-
plex and poorly understood, current treatment primarily relies
on antimalarial drugs and supportive care. Here we focus on
recent advancements in understanding the molecular patho-
genesis of CM and the variable presentations between children
and adults.
Several pathogenetic mechanisms have been proposed for
CM including mechanical microvascular obstruction by seques-
tered infected erythrocytes (IEs),7 activation of immune cells
and release of pro-inflammatory cytokines,8,9 endothelial dys-
function,10 dysregulation of coagulation pathways,11,12 blood–
brain barrier (BBB) permeability,13 and brain swelling.14
Furthermore, autopsy studies have subdivided pediatric cases
into two different groups based on histopathological patterns.
The CM1 group has sequestration only, while CM2 group has
sequestration plus vascular pathology (ring hemorrhages,
fibrin-platelet thrombi, and monocytes).15,16 Ring hemor-
rhages and cerebral thrombosis are also described in a pro-
portion of adult cases,17 but whether there is an equivalent
CM1/CM2 dichotomy in adults is less clear. Recent find-
ings implicate a specific subset of parasites that adhere to
endothelial protein C receptor (EPCR) in severe childhood
malaria.18 As EPCR plays a key role in regulating coagula-
tion and endothelial cytoprotective and barrier properties,19
this raises the possibility there may be linkages between
IE cytoadhesion and microvascular complications in CM.20
However, the precise molecular processes that account for
the pathophysiological differences between CM1, CM2, and
adult CM are poorly understood. Elucidating key pathogenetic
mechanisms in CM and severe malaria may suggest new treat-
ment options to improve patient outcomes.
Unlike P. falciparum, P. vivax rarely causes severe disease in
healthy travelers and is a less deadly parasite.21 Factors that
may contribute to the lower virulence are that P. vivax only
infects reticulocytes and the absence of the cytoadhesion protein
family responsible for sequestration in P. falciparum infec-
tions.21,22 These differences limit the blood-stage parasite
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burden and spectrum of cytoadhesion-based complications.
Another distinction is thatP. vivax has dormant liver hypnozoite
stages, which can reactivate and lead to blood-stage relapses.
Relapses contribute to vivax morbidity, but the mechanisms
leading to severe vivax disease remain to be elucidated. This
review covers recent findings on the pathological pathways in
pediatric and adult CM, as well as severe malaria cases in low-
transmission settings in South America and India because of
P. vivax infections, highlighting progress and outstanding ques-
tions in severe malaria pathophysiology in the context of the
pathogenesis research activities within the International Centers
of Excellence forMalariaResearch (ICEMR) program.
SEVERE FALCIPARUM MALARIA IN
CHILDREN AND ADULTS
The clinical presentations of severe falciparum malaria dif-
fer between children and adults.5 In particular, adults have a
higher mortality rate and more multiorgan system involve-
ment than children. A recent large multicenter comparison of
artesunate versus quinine in the treatment of severe malaria
in adults and children reported adult and pediatric mortality
rates of 18.5%23 and 9.7%, respectively.24 The major organs
affected in adult severe malaria are brain (CM), lungs (acute
respiratory distress syndrome [ARDS]), liver ( jaundice), and
kidneys (acute renal failure) (Figure 1). Although the overall
mortality of adult CM is about 15–20%, the risk of death
depends on associated vital organ dysfunction and is increased
3-fold in the presence of acidosis and renal failure.25 In chil-
dren, the three major disease complications are CM, severe
anemia, and acidosis, but ARDS and renal failure are rare
(Figure 1).26 Although the three disease syndromes can occur
singly or as overlapping syndromes, severe malaria anemia
commonly affects younger children, and CM and metabolic
acidosis are more commonly found in slightly older children.27
CM and metabolic acidosis are each associated with high mor-
tality rates in children (12% and 14%, respectively), and the
presence of both increases the risk of death.28 The severity of
disease may be exacerbated by both higher parasite burdens
and the tissue-specific patterns of IE sequestration. Thus,
there is significant research effort to understand factors that
contribute to parasite blood-stage multiplication potential and
cerebral homing of IEs.
Although severe malaria predominantly affects African chil-
dren in high-transmission settings and adults in lower trans-
mission settings, the same differences in disease complications
and mortality were observed between adults and children in
Rourkela, India.29 Collectively, these findings suggest there are
different pathophysiological diseasemechanisms in children and
adults, but the molecular mechanisms underlying these differ-
ences are not fully understood. The different clinical symptoms
could result from differences in host malaria immune status,
since malaria transmission intensity is much higher in Africa
than other regionswhere adults experience severemalaria.Alter-
natively, they could potentially relate to different parasite binding
types, human polymorphisms, or age-dependent changes in the
vascular system response to falciparum-induced inflammation.
P. falciparum and cerebral malaria: a histopathological and
ultrastructural perspective. A major pathological feature of
P. falciparum malaria is that the mature stage IEs sequester
from blood circulation by binding to the endothelial lining
of blood vessels. Histopathological studies of fatal malaria
had largely focused on adults in hypoendemic areas30,31 and
soldiers in military theatres,17 until recently, when a group
based in Malawi undertook a case–control study, comparing
the gross and microscopic pathology in children dying with
clinically defined CM to the pathology in malaria-infected
children with non-malarial causes of death.16
FIGURE 1. The major clinical complications associated with adult and pediatric severe malaria. Clinically severe malaria is a multisystem dis-
order that can affect different organs and differs in presentation between children and adults. The major clinical complications in children are
cerebral malaria, severe malaria anemia, and metabolic acidosis. In adults, cerebral malaria is frequently accompanied by multiorgan system
complications, including metabolic acidosis, acute kidney failure, jaundice, and acute respiratory distress (ARDS).
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FIGURE 2. Schematic representation of the pathological differences between cerebral malaria CM1 and CM2. Autopsy studies in children
have divided CM cases into two groups based on histological features,16 CM1 cases have infected erythrocyte sequestration in the cerebral
microvasculature and no associated vascular pathology. CM2 cases are defined by cerebral sequestration plus intra- and perivascular pathology,
including ring hemorrhages, fibrin-platelet thrombi, and intravascular monocytes. In the CM2 group, infected erythrocyte (IE) sequestration is
frequently associated with fibrin-platelet thrombi in both capillaries and postcapillary venules. Insets provide examples of pathological features
observed in CM2 cases described in Dorovini-Zis and others.15 Inset (A) shows a small branching capillary in which the upstream region is
filled with sequestered IEs and one of the branches is occluded by a thrombus. This event is associated with a ring hemorrhage in which the
microvessel is partially denuded of endothelial cells and is surrounded by a zone of necrosis and a ring of uninfected red blood cells in the white
matter. Inset (B) shows a small vessel packed with sequestered IEs and surrounded by extravasated fibrinogen indicating increased permeability
of the blood–brain barrier. Inset (C) shows a micovessel filled with monocytes containing phagocytosed hemozoin pigment. Intravascular
pigmented monocytes are found adherent to the microvessel wall, but do not transverse across the blood–brain barrier. The molecular mecha-
nisms driving the CM1 and CM2 pathophysiology are incompletely understood. Intercellular adhesion molecule 1 (ICAM-1) and endothelial
protein C receptor (EPCR) are candidate brain endothelial receptors,18,31 but it is not known if the same parasite adhesion types are associated
with CM1, CM2, and adult CM (not pictured). Recent studies reported that binding of IE to EPCR was associated with the development of
severe malaria18 and that decreased EPCR staining on endothelial cells and increased fibrin deposition occurred at the site of IE adhesion in
cerebral microvessels during fatal pediatric CM.20 This association suggests there may be causal links between cytoadhesion and microvascular
pathophysiology. However, fibrin deposition is not found in CM1 and is less prominent in adult CM, highlighting gaps in our understanding of
CM pathophysiology.
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A striking finding was that ~25% of children who met the
standard clinical case definition of CM during life (P. falciparum
parasitemia, Blantyre Coma Score ≤ 2, no other obvious cause
of coma)32 had no evidence of the pathological hallmark of
CM, the cerebral sequestration of IE. All of these children had
a non-malarial cause of death identified at autopsy.16 This find-
ing highlights the difficulty of assigning the true cause of coma
in children in geographic regions with high rates of apparently
asymptomatic malaria infections and emphasizes the need for
better CM diagnostics to guide treatment decisions. Among
those who did have evidence of cerebral sequestration of IEs
(“true CM”), two distinct pathological patterns were noted,
CM1 and CM2 (Figure 2). Approximately one-third of the
true CM patients had histologic evidence of sequestration
only (CM1); the other two-thirds had evidence of intra- and
perivascular pathology (fibrin thrombi, “ring” hemorrhages
involving uninfected red cells, and intravascular accumulation
of white blood cells).16 Although fibrin and intravascular mono-
cytes are less prominent features in adult CM autopsy studies,
ring hemorrhages are found in approximately 30–50% of adult
cases (Table 1). Furthermore, in the classic histopathological
study of Spitz17 onWorldWar II U.S. military soldiers who died
of acute falciparum malaria, thromboses and ring hemorrhages
were commonly observed together, leading Spitz to speculate
that ring hemorrhages were caused by thrombosis. Thus,
although the CM2 pattern is not commonly described in adult
cases (Table 1),42 it is possible that thrombotic lesions may play
a role in some adult CM cases. Overall, the variability of patho-
logical findings indicates that CM is not a histologically uniform
syndrome and suggests there may be different pathophysiologi-
cal mechanisms in CM1 and CM2, and potentially between
children and adults.
From histopathological studies, activation of endothelial
cells31 and breakdown of the BBB are evident.15,39,43 Parasites
can stimulate intracellular signaling events in endothelial cells
whether through direct adhesion to receptors such as CD36
or intercellular adhesion molecule 1 (ICAM-1)44,45 or release
of soluble factors.45,46 This affects cerebral endothelial cell
structure and function, which in turn may mediate changes in
the BBB function in CM,13 but the parenchyma of the brain
is rarely involved. Nevertheless, in both children and adults,
neuropathology has been associated with ring hemorrhages
(Table 1), and if sufficient time has passed after an insult
Durck’s granulomas can develop at sites of ring hemorrhage.
Durck’s granulomas are occasionally seen in adults,17 but are
extremely rare in children.33 More commonly, areas of demye-
lination are associated with IE sequestration in children15 and
areas of axonal injury/activation or myelin loss have also been
described in adult CM.40 However, the overall pattern of injury
varies between children and adults. The molecular mechanisms
underlying these differences still remain to be elucidated.
Increased brain volume was evident in all true CM cases in
the Malawi series,33,42 but is not universal in adults.47,48 Several
possiblemechanismsmay contribute to increased brain swelling,
including 1) increased blood volume resulting from microvas-
cular congestion generated by sequestered IEs and decreased
venous outflow; 2) cytotoxic edema (BBB remains intact but
accumulation of intracellular fluid due to altered metabolism or
movement of water into brain cells occurs); 3) vasogenic edema
(BBB is disrupted); and/or 4) increased cerebral blood flow
volume in response to fever, anemia, and seizures. Understand-
ing the relative contribution of these potential mechanisms to
brain swellingmay suggest treatment strategies.
Imaging approaches to investigate disease pathogenic
mechanisms. As illuminating as autopsy studies have been,
they are inherently limited by the necessity of only studying
patients who have died, and by only studying them at one
point in the process, the time of death. Imaging modalities that
could be used during life, which could be repeated to capture a
process, would be helpful in studies of malaria pathogenesis.
Orthogonal polarization spectral imaging. Clear images of
microcirculatory blood flow in mucosal surfaces (sublingual,
rectal) obtained via orthogonal polarization spectral imaging
allow for “real-time” visualization of microvascular obstruc-
tion related to sequestered IEs.49 This approach has revealed
significant disturbances in microvascular blood flow that were
variable between adjacent microvessels and increased in pro-
portion to disease severity. These abnormalities disappeared
after patient recovery, highlighting an important role for
reduced microcirculatory blood flow in severe malaria.
TABLE 1
Histological characteristics of pediatric and adult CM
Characteristic
Pediatric Adult
CM1 CM2 CM
Intravascular pathology
Infected erythrocytes in microvessels of gray and white matter Yes15,16,33 Yes15,16,33 Yes34,35
RHs No15,16,33 Yes15,16,33 Yes, subset7,17,30,36–38
Increased BBB permeability to plasma factors associated with RH NA15 Yes15 Yes13
Increased BBB permeability to plasma factors associated with
sequestered IEs
Yes15 Yes15 Yes13,39
Microvascular thrombosis associated with necrosis of endothelial lining
and perivascular hemorrhages
No15 Yes15 Limited
Fibrin thrombi No15,16,33 Yes15,16,33 Rare30,31,37
Pigment-containing monocytes No15,16,33 Yes15,16,33 Yes37,40
Perivascular pathology
Reactive astrocytes Yes15 Yes15 Yes40
Durck’s granuloma (reactive microglia, astrocytes, and lymphocytes) No15 Extremely rare33 Occasional41
Axonal injury associated with RH or vascular thrombosis NA Yes15 Yes40
Myelin loss associated with RH NA Yes15 Yes40
Diffuse myelin damage associated with sequestered IEs Limited15 Yes15 ?
Axonal injury associated with sequestered IEs Yes15 Yes15 ?
BBB = blood–brain barrier; CM = cerebral malaria; IEs = infected erythrocytes; NA = not applicable; RHs = ring hemorrhages; ? = not reported.
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However, because the expression of surface receptors varies
between organs,50 what is seen in accessible areas may not
reflect what is happening in the brain.
Ocular funduscopy. The eye and the brain have similar
embryologic origins, and themicrovasculatures of the two organ
systems share important features.51 In addition, the optic fundus
can be readily observed and studied during life in patients with
severe malaria. In conjunction with the Malawi autopsy study,
ophthalmologists described a unique malarial retinopathy con-
sisting of white-centered hemorrhages, vessel color changes,
and peri- and extramacular whitening.52 At least one of these
findings was present in all cases of true CM (i.e., patients with
evidence of cerebral sequestration of IEs at autopsy), and
although recognition of the retinopathy requires a trained
observer with relatively expensive equipment (direct and indi-
rect ophthalmoscopes), it has created the opportunity, exploited
by the ICEMRprogram, to use amore specific clinical case defi-
nition of CM. Retinal hemorrhages correlate, numerically, with
the ring hemorrhages seen in fatal cases of pediatric CM.53
Vessel color changes reflect the presence of sequestered, para-
sitized, and de-hemoglobinized red cells,54 while the whitening
represents areas of impaired perfusion.55
Ophthalmologic observations on adults with severe malaria
are relatively sparse, but they are consistent with the reported
pediatric findings in that approximately one-third of adults
meeting the standard clinical case definition of CM have no
evidence of malarial retinopathy.56 Retinal hemorrhages are
commonly observed,57 but vessel color changes, seen in ~32%
of children with CM,58 are only rarely seen in adults.56 The
severity of malaria retinopathy is strongly associated with
malaria mortality in both adults and children.51,56
Neuroimaging. Neuroimaging neatly addresses the two pri-
mary deficiencies of the autopsy approach: survivors can be
imaged and serial studies can be carried out throughout the
course of the acute illness. However, the worldwide distribu-
tion of sophisticated radiological capacity does not include
malaria-endemic areas, so most descriptions of neuroimaging
findings in malaria patients have been single case reports from
patients hospitalized in more developed countries.14
Computed tomography scan technology is relatively uncom-
plicated and affordable, and the process itself is quick. This
approach was the first used to illuminate disease pathogenesis
in malaria patients, and highlighted the importance of increased
brain volume.59–61 Most of these studies were done before the
importance of malarial retinopathy was recognized, though the
possibility of classification errors complicates interpretation of
these findings.
Individual case reports of magnetic resonance imaging (MRI)
findings in patients with CM (as reviewed in reference 59) have
described a variety of findings, all of which have been corrobo-
rated by larger, systematic studies in Thai adults62 andMalawian
children.63 Increased brain volume is strongly associated with
a fatal outcome in children.64 Cortical involvement (often
restricted to specific lobes), and changes in the periventricular
white matter, the corpus callosum, and the thalami are common
in childrenwith retinopathy-positive CM.
Both of the larger studies were limited by the strength of the
magnet (0.2 tesla [T] in Thailand, 0.35 T inMalawi).A collabora-
tive effort between two independent ICEMR projects (Table 2)
will address this problem while simultaneously addressing dis-
parities between the clinical manifestations of severe disease in
adults and children. The joint effort is currently being carried
out between two hospitals, one located in Malawi and one in
India, both of which have MRI facilities. Adults and pediatric
patients with severe malaria in India (retinopathy-positive CM,
with and without other organ system involvement) will undergo
MRI on a 1.5 T machine, and their findings will be compared
with those in retinopathy-positive CM pediatric patients in
Malawi. The clinical protocol has been standardized between
the two field sites, and four MRI sequences will be common to
both projects, as their magnet strengths are different. To ensure
the accurate interpretation and comparison of MRI findings in
TABLE 2
ICEMR activities related to severe malaria
ICEMR Research activities related to pathogenesis of malaria
Southeast Asia Collecting descriptive data on malaria patients attending local hospitals at sentinel sites,
including data on disease manifestation
South Asia (India) Investigating the molecular and cellular basis of severe Plasmodium falciparum and severe
Plasmodium vivax infections in hospital patients recruited at multiple locations in India
India Assessing the role of interindividual variations in endothelial responsiveness to TNF in the
development of cerebral malaria
Investigating the pathology of cerebral malaria in India patients using novel MRI techniques
Collaborating with the southern Africa ICEMR (Malawi) on MRI findings in adults and
children with severe malaria
East Africa (Uganda) Investigating the role of prompt and effective therapy for minimizing the risk of severe malaria
in cohorts of children living in high-endemic settings
Collecting descriptive data on characteristics and outcomes of children admitted with severe
malaria at six public hospitals in Uganda
Southern African (Zambia/Zimbabwe) Collecting descriptive data on clinical diagnoses for persons seeking care at rural health centers
Southern Africa (Malawi) Collecting hospital-based data on febrile illnesses (malarial and non-malarial)
Collaborating with south Asia ICEMR (India) on MRI findings in adults and child
Amazonia Observational, hospital-based observations of severe P. vivax malaria; 16S rRNA molecular
and blood culture analysis of severe malaria cases
Latin America (outside Amazonia) Clinical profile of malaria in different epidemiological settings in Colombia, and their
association with parasite and host immunological status
Determine the effects of immune status, nutritional factors, and helminth coinfection on
complicated malaria cases in Colombia
Southwest Pacific Collecting data on childhood severe malaria admissions to major hospital serving
Madang Province
ICEMR = International Centers of Excellence for Malaria Research; MRI = magnetic resonance imaging; TNF = tumor necrosis factor.
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these sequences, all the images will be scored and shared
between the radiologists, via a web-based platform to enhance
standardization.65 This study will permit, for the first time, the
clinical characterization of pediatric and adult CM by neuroim-
aging and a precise comparison of carefully clinically defined
cohorts of CM patients of different ages and from different
continents. Such extensive MRI techniques have never been
applied systematically to patients with acute malaria and repre-
sent a promising approach to investigating the relationship
between brain swelling and the onset of CM.
Vascular activation/dysfunction and coagulation pathways
in severe malaria. The brain swelling observed during CMboth
in Indian adults and Malawian children might be the conse-
quence of disruption of the BBB associated with the pathoge-
netic processes of CM, resulting in vasogenic edema. This
hypothesis is currently being investigated as part of a Malawi–
India inter-ICEMR initiative (Table 2) and is in line with the
emergence of the endothelial cell as a central player in the path-
ophysiology of the neurologic syndrome. Although its involve-
ment as a substrate for IE sequestration in the brain was
identified very early on,66 results published over the past decade
have highlighted the complex role of cerebral endothelial cells
in the development of CM. One of the main goals of the India
ICEMR is to investigate parameters inherent in the host endo-
thelium that may result in an increased susceptibility to severe
malaria in Indian adults infected with P. falciparum, an axis of
research that is divided into threemain approaches.
Variations and heritability of the host endothelial respon-
siveness to tumor necrosis factor alpha. A central component
of CM pathophysiology is the activation of microvascular
endothelial cells, resulting from both the cytoadherence of IE
to their surface and the pro-inflammatory effects of local and
systemically released cytokines.67 The consequences of this endo-
thelial inflammation are numerous and include the upregulation
of endothelial receptors for enhancing IE and platelet seques-
tration; the further release of cytokines and chemokines and
the trigger of a tumor necrosis factor (TNF)–dependent pro-
apoptotic pathway (as reviewed in reference 68). We hypothe-
sized that variation in the responsiveness of endothelial cells to
TNF in different individuals could be a factor affecting the sever-
ity of disease in patients infected with P. falciparum (Figure 3A).
Indeed, endothelial cells derived from CM and uncomplicated
(UM) children patients from Malawi were shown to display
significantly different ex vivo responsiveness to TNF.When com-
pared with UM, CM-derived endothelial cells express signifi-
cantly higher levels of parasite and platelet receptors, produce
more endothelial microparticles, release more pro-inflammatory
cytokine, and are more prone to undergo apoptosis on stimu-
lation with TNF.69 On the basis of these results, it was hypothe-
sized that genetic variations within promoter, intron, or exon
sequences of endothelial inflammatory genes may, in part, deter-
mine the clinical course in CM patients, as has been described
in sepsis.70
Using a large number of freshly isolated microvascular endo-
thelial cells from adult patients admitted to Ispat General
Hospital in Rourkela, we are planning to compare the response
to TNF between CM and UM patients from India and investi-
gate the different factors, extrinsic or intrinsic, leading to the
FIGURE 3. Proposed influence of the host endothelial responsiveness to tumor necrosis factor (TNF) on the severity of malaria infection.
Low endothelial TNF responders are less prone to upregulate receptors involved in the sequestration of infected erythrocyte (IE) and platelets
than high responders. This leads to a minimal adhesion of IE and host cells and a lower pro-apoptotic signal for the endothelial cells, which
might account for the absence of pathology. High responders, however, are over-activated in the presence of TNF, leading to high adhesion of
IE and a strong pro-apoptotic signal, possibly resulting in the breakdown of the blood–brain barrier and, ultimately, to vasogenic edema (A).
Potential clinical benefits offered by angiopoietin (Ang)-1 as a quiescence agent for high TNF-responding endothelial cells during cerebral
malaria (CM) (B).
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interindividual differential activation of the endotheliumbetween
the two patient categories. The comparative analysis of the
variation in transcripts between the two high and low TNF-
responding groups of endothelial cells will give us insights into
the pathways involved in the acute activation observed in CM
patients, and will be compared with the results obtained in
Malawian children. This project is carried out not only with a
view to understanding the molecular basis of disease but also
to identifying patients at risk by analyzing specific single nucle-
otide polymorphisms associated with high and low responders.
It will also assess if there are age-specific differences in endo-
thelial responsiveness. Understanding the mechanistic basis
of vascular dysfunction in severe malaria may suggest new
treatment options.
Reversibility of the systematic endothelial activation in CM
patients. The presence of TNF as a trigger of inflammation in
malaria led to the assessment of a TNF-blocking approach
in CM. Although in vitro treatments produced favorable
results, anti-TNF clinical trials failed to reduce mortality in
these patients.71,72 The use of a targeted compound block-
ing the downstream endothelial activation signaling cascade
resulted in a reduction of endothelial inflammation in vitro.73
However, this effect was only observed when the compound
was administered simultaneously with the cytokine, which
would be effectively impossible in vivo. Since most of the
patients admitted to the ward have already high levels of
TNF, an acute therapy might work by dampening the existing
endothelial inflammatory response in CM patients. Angio-
poietin (Ang)-1 has recently become a topic of increasing inter-
est in endothelial cell quiescence and survival,74 and plasma
Ang-2/Ang-1 ratio has been shown not only to be crucial for the
endothelial activation but also to discriminate UM and CM.
Indeed, high levels of Ang-2 are associated with mortality in
patients with CM, whereas high levels of Ang-1 are associated
with UM (as reviewed in reference 75). Since the use of Ang-1
offers clinical benefits as a quiescence agent for endothelial cells
in an elegant model of sepsis,76 it is conceivable that restoring
the Ang-2/Ang-1 balance in favor of Ang-1 would block and
potentially reverse the ongoing inflammatory processes in CM
patients at the time of admission (Figure 3B).
The potential clinical benefits of Ang-1 are currently being
evaluated as part of the ongoing project on primary endothe-
lial cells at Ispat General Hospital. Using the endothelial cell
banks isolated from CM patients, the effects of Ang-1 on
TNF-stimulated endothelium will be measured, with a view to
develop new adjunct therapies and improve disease outcome
in CM.
The role of EPCR in adult CM. Recent studies reported
that binding of IE to EPCR was associated with the develop-
ment of severe malaria18 and that decreased EPCR staining
on endothelial cells and increased fibrin deposition occurred
at the site of IE adhesion in cerebral microvessels during fatal
pediatric CM.20 A causal relationship between cytoadhesion
and coagulopathy was therefore suggested for the first time,
and the pivotal role of EPCR in the organ specificity of the
syndrome was proposed.77,78 One of the major aims of the
India ICEMRs is to further investigate the role of EPCR in
the development of CM in Indian adults, as fibrin deposition is
a far less prominent pathological feature in southeast Asian
adults than African children who succumb to CM (Table 1).20,30
Since endothelial cell cultured from subcutaneous fat resemble
cerebral vascular endothelial cell and represent a useful ex vivo
model for examining brain endothelial alteration in the con-
text of CM,69 this approach is being carried out by performing
phenotypical analyses of primary subcutaneous endothelial
cells isolated from patients admitted at Ispat General Hospital,
followed by targeted gene expression profiling (RNA and
miRNA) and genetic analyses of genes selected for their rele-
vance in the protein C pathway. The results will 1) contribute
to a better understanding of the pathogenic mechanisms for
childhood and adult disease, 2) assess the overall importance
of EPCR in mediating the cytoprotective effects of activated
protein C (APC) in the brain, and 3) evaluate new avenues of
translational research. A collaborative protocol is currently
being developed between the India ICEMR and the clinical
team to extend these analyses to endothelial cells isolated
from postmortem brain biopsies samples of fatal CM.
Parasite biomass and severe malaria. It is difficult to mea-
sure the total parasite biomass of P. falciparum (circulating and
sequestered) from blood sampling because of the “hidden”
sequestered component. To overcome this challenge, a new
approach has been introduced byDondorp and others79 in which
the plasma concentration of a soluble parasite molecule serves
as a surrogate for the total parasite biomass. Plasmodium
falciparum histidine-rich protein-2 (HRP-2) is a water-soluble
protein produced throughout the parasite life cycle and released
largely (but not exclusively) at the time of schizont rupture.79,80
It has a long half-life and persists in the plasma for up to 21 days,
even after successful treatment81; HRP-2 detection (present/
absent) is the basis of many rapid diagnostic tests, but quantita-
tive measures of HRP-2 can discriminate between retinopathy-
positive and retinopathy-negative CM,82 can predict which
children with uncomplicated malaria are more likely to deteri-
orate,83 and can distinguish between patients with complicated
malaria, mild malaria, asymptomatic parasitemia, and non-
malarial fevers.84 A model, based on plasma half-life of HRP-2
in vivo¸ production rates of HRP-2 in vitro, and parasite multi-
plication rates suggests that HRP-2 concentrations reflect total
body parasite burden (sequestered and circulating parasites).79
In general, the associations between HRP-2 concentration and
disease severity support the hypothesis that parasite biomass
is a major determinant of malaria pathogenesis. However, a
recent longitudinal birth cohort study of Tanzanian children
followed from birth to 2–4 years of age indicated that while
parasite burden was higher on average in severe malaria epi-
sodes, high parasite burden was insufficient to cause severe
disease.85 Thus, high parasite burden appears to be an impor-
tant determinant in severe malaria, but other factors may act in
concert to precipitate severe malaria episodes.
Parasite invasion pathways and malaria severity. Higher
parasite biomass is a risk factor for severe malaria and may be
driving increased systematic inflammation, endothelial activation
markers, and metabolic acidosis by microvascular obstruction.
The circumstances leading to higher parasite burdens in severe
malaria are likely multifactorial and incompletely understood.
However, potential parasite factors are red blood cell (RBC)
invasion efficiency and the cytoadhesion efficiency of infected
RBCs. Mathematical modeling approaches suggest that inva-
sion efficiency can be a significant driver of peak parasite den-
sity during an infection and concomitant pathogenesis.86 Rodent
malaria parasites can shift from a nonlethal to a lethal form
following a change in preference from reticulocytes to older
normocytes resulting in huge increases in parasite biomass and
pathology.87 In humans, there is evidence that the efficiency
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of the invasion process can be a virulence determinant in
P. falciparum parasites.88 Clearly, this can be influenced by
genetic polymorphisms within both the host and the parasite, as
well as acquired immunity. In addition, the ability of parasites to
invade RBCs using alternative receptors, known as invasion path-
ways, can facilitate immune evasion and persistence of malaria
infections89 and ultimately contribute to malaria pathogenesis.
Anemia may result from chronic low-burden infections.90
Invasion potential has been measured in two ways: by para-
site multiplication rate and by selectivity of RBCs. Both have
been shown to be strongly associated with the severity of
P. falciparum malaria in one population in southeast Asia,88
suggesting the existence of parasite molecular factors that medi-
ate pathogenesis through increased proliferation. However, a
similar study was carried out with parasite isolates from Africa
and no association was found between invasion efficiency, selec-
tivity, and disease severity.91 It is not clear whether this is due to
regional differences in parasites or in host factors, such as the
level of acquired antimalarial immunity.
Previous work carried out in several varied geographical
areas have shown that natural P. falciparum isolates are capa-
ble of using multiple ligand–receptor invasion pathways, and
exhibit variation in pathway usage, suggesting mechanisms by
which invasion efficiency could be altered via parasite-based
mechanisms. These studies have shown that both sialic acid–
dependent and sialic acid–independent invasion pathways are
commonly used by parasites collected directly from infected
humans, and a few isolates have been shown to be able to
switch between the use of sialic acid–dependent and sialic
acid–independent pathways. Switching of one isolate was asso-
ciated with reduced invasion efficiency.89
With the genome sequenced, Plasmodium parasites have
been found to possess a diverse number of ligands for invasion.
Two superfamilies of invasion ligands, the reticulocyte-binding-
protein-like (RBL) and the erythrocyte-binding-protein-like
(EBL) have been identified.92 Much data from studies with
P. falciparum suggests that each parasite ligand has a single cog-
nate receptor, defining alternative invasion pathways and that
there is a hierarchy of different ligand–receptor interactions.
Further, variation can exist at the level of sequence and expres-
sion changes for these invasion ligands, suggesting a molecular
basis for switching between the use of different invasion path-
ways, either for immune evasion, to change the parasite multi-
plication rate, and/or RBC selectivity. To better understand the
molecularmechanisms driving higher parasite burdens in severe
malaria, an ICEMR group in India is addressing the interplay
between parasite invasion efficiency and IE cytoadhesion phe-
notypes in disease severity.
Parasite adhesion and severe malaria. As described above,
cytoadhesion of IEs is a major virulence determinant for CM
complications. Furthermore, high parasite burdens and the
massive sequestration of IEs in different tissue beds and
resulting microvascular obstruction may lead to metabolic aci-
dosis.4 The majority of falciparum infections are not severe,
which suggests that the parasite is relatively well adapted to
sequester in microvessels without killing the host. Cytoadhesion
of IEs is predominantly mediated through the var gene/
P. falciparum erythrocyte membrane protein 1 (PfEMP1) fam-
ily of adhesion proteins.93–95 PfEMP1 proteins are anchored
at parasite-induced, knob-like protrusions on the erythrocyte
membrane,93 exposing them to host antibodies. Clonal anti-
genic variation of var genes enables P. falciparum to evade anti-
body destruction and to bind to different host receptors.96 Each
parasite encodes approximately 60 different var copies97 with
limited overlap of var gene repertoires between parasite haplo-
types.98 The vast intra- and interstrain diversity in PfEMP1
repertoires enables parasites to establish chronic infections
and repeatedly infect hosts with different parasite genotypes.
A fundamental question for pathogenesis is whether specific
PfEMP1 and host-receptor interactions have a causal role in
severe malaria.
Despite extensive sequence diversity, the majority of var
genes can be classified into threemain subfamilies (A, B, andC)
on the basis of upstream gene sequence and chromosomal loca-
tion.99 Interstrain sequence comparisons have also identified
three unusual strain-transcendent var genes (var1csa, var2csa,
type 3 var).100–102 Each PfEMP1 protein encodes multiple adhe-
sion domains called Duffy binding-like (DBL) and cysteine-rich
interdomain region domains.95 PfEMP1 adhesion domains are
classified into different types (α, β, γ, δ, etc.) and subtypes based
on sequence similarity.101,103 Using adhesion domain classifica-
tion, interstrain sequence comparisons have revealed a small
number of tandem domain arrangements of 2–4 domains, called
domain cassettes (DC), which are unusually conserved between
parasite genotypes.101
The prototypical example of a specific PfEMP1 and disease
is malaria in pregnancy. In this case, the strain-transcendent
VAR2CSA mediates placental binding.104,105 It has been more
challenging to determine if a specific PfEMP1 subset is associ-
ated with CM because of the difficulty of studying the brain.
Analysis of var gene expression in patients has suggested that
most infections contain a heterogeneous population of para-
sites expressing a mixture of A, B, or C var genes. In hosts
with limited malaria immunity and severe pediatric malaria,
the ratio of PfEMP1 variants appears to be skewed toward
higher group A expression.106–108 These findings suggest that
group A PfEMP1 encode adhesion traits that facilitate para-
site multiplication in malaria naive hosts and may include
binding properties that predispose to severe malaria. As indi-
viduals acquire anti-PfEMP1 antibodies through repeated infec-
tions, the proportion of group B and C variants appear to
increase.108,109 However, even in pregnant African women who
have acquired considerable antimalarial immunity, there was
high var2csa expression from parasites recovered from placenta,
but mixed var2csa and A, B, C var expression from parasites
circulating in the blood.110 Thus, the parasite strategy of having
a heterogeneous population appears to persist even after indi-
viduals have acquired substantial antimalarial immunity.106–108
More recently, it was shown that parasites expressing
PfEMP1 proteins encoding DC8 or DC13 are strongly selected
on human brain microvascular endothelial cells in vitro111,112
and are highly expressed in children with severe malaria or
CM.113 The DC8 is found in an unusual chimeric gene between
groups B and A and the DC13 is restricted to group A vari-
ants. Both DC8 and DC13 proteins, as well as a subset of other
group A variants, were found to encode a novel binding prop-
erty for EPCR,18 the receptor for APC. As the APC–EPCR
pathway plays a key role in regulating blood coagulation and
endothelial barrier properties,19,114 this has raised the possibil-
ity that there may be a linkage between IE binding and CM
pathogenesis. However, given the different clinical presenta-
tion and autopsy findings in children and adults (Table 1),5 an
important question is whether different PfEMP1 variants are
associated with CM1, CM2, and adult CM.
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As discussed above, one possibility is that host polymor-
phisms or age-specific differences in endothelial responses may
contribute to pathophysiological differences. Alternatively, dif-
ferent parasite binding variants may be associated with CM1,
CM2, and adult CM. For instance, ICAM1 has also been pro-
posed to be a cerebral sequestration receptor.31 Therefore, one
possibility is that ICAM1+, EPCR− binding variants play a more
predominant role in CM1 where fibrin-platelet clots and ring
hemorrhages are absent, whereas EPCR+ binding variants are
predominant in CM2 (Figure 2). To evaluate if parasite binding
phenotype influences disease pathogenesis, more information is
needed on the binding specificity of DC8, DC13, and other
group A–expressing parasites for ICAM1 and EPCR.111,112
In addition, multiple domains in DC8 PfEMP1 bind to brain
endothelial cells.115 Therefore, this analysis should include
defining the other host receptors that act in concert with EPCR
to mediate firm endothelial binding, as these adhesion traits
may also influencemicrovascular pathology.
Although considerable work has been done on var gene
expression in severe pediatric malaria,18,107,108,113,116 almost no
information exists on DC8 or DC13 var gene expression in
adult severe malaria. One of the aims of the India ICEMR is
to investigate the expression of var genes in Indian adults.
This question is also being evaluated as part of a collaborative
effort between multiple independent ICEMRs using carefully
clinically defined cohorts, in which patients in India have
undergone MRI, fundoscopic examinations and have been
evaluated for endothelial responsiveness to TNF. By having a
precise comparison between MRI and fundoscopic findings,
PfEMP1 expression, and host endothelial phenotypes, it may
be possible to distinguish if host or parasite factors contribute
to different pathological manifestations.
SEVERE VIVAX MALARIA IN CHILDREN
AND ADULTS
The other major Plasmodium species infecting humans is
P. vivax. Although P. vivax infections are rare in most of
Africa because of the high percentage of the human popula-
tion with the Duffy blood group antigen–negative phenotype
that is highly resistant to RBC invasion,117,118 it is estimated
that over 2.5 billion people are at risk of P. vivax transmission.
Approximately 91% of the populations at risk of transmission
are in central and southeast Asia.117 Furthermore, in Brazil,
P. falciparum cases are declining, and P. vivax has become the
dominant parasite species in many endemic areas.119
Historically, P. vivax has been considered a relatively benign
parasite, but recently there has been a renewed appreciation
that it carries a significant morbidity and mortality burden in
endemic regions.21,120,121 Furthermore, a 5–15% mortality rate
was reported in the early neurosyphilis therapies of patients
with P. vivax.120 Part of the explanation for the “benign” repu-
tation, despite the evidence for mortality, is that vivax parasites
are highly restricted to reticulocytes and therefore cannot
achieve the same high parasite biomass as P. falciparum.4 A
second difference is that P. vivax possesses relatively poor IE
adhesive capacity compared with P. falciparum.122 Major ques-
tions for vivax pathogenesis include how does a parasite that is
limited to lower grade parasitemias cause severe malaria? And
is severe disease a consequence of vivax infection alone, the
relapsing nature of P. vivax, or do other comorbidities influence
disease severity? Within the ICEMRs, work is being done to
better understand the prevalence and severity of P. vivax infec-
tions in Latin America and Asia and to characterize factors
that may contribute to disease severity.
Clinically, vivax infections are associated with a chronic debil-
itating febrile illness that can be accompanied by chills,
vomiting, malaise, and headache.21 On a per parasite basis,
P. vivax is highly potent at inducing pro-inflammatory cytokines,
such as TNF21,120,121,123,124 and has a much lower pyrogenic
threshold than P. falciparum (180 vivax parasites/μL compared
with 1,000 falciparum parasites/μL).124,125 The most frequent
severe complications of vivax infection are severe anemia and
acute respiratory distress.121 Cerebral malaria is a rare compli-
cation of P. vivaxmono-infection, although it has been reported
in India.126 In general, even less is known about the pathoge-
netic mechanisms in vivax malaria than P. falciparum, and it is
not known if P. vivax CM cases reflect a particular strain of
P. vivax, and/or a region-specific host susceptibility.
Parasite adhesion and severe vivax malaria. Unlike
P. falciparum, P. vivax IEs become more deformable as they
mature,127 and all parasite stages are visible in peripheral blood
smears.21 However, late-stage schizont forms are underrepre-
sented in peripheral blood,119 suggesting sequestration may
occur. The lack of a continuous culture system has hindered
research into P. vivax cytoadhesion, but the mechanism is dis-
tinct from P. falciparum becauseP. vivax IEs lack knob-like pro-
trusions and do not encode var genes.22 Ex vivo studies have
shown that P. vivax IEs adhere to placental cryosections as well
as human lung—albeit at 10–15 times lower binding levels than
P. falciparum.128 A strong candidate for P. vivax cytoadhesion
and rosetting functions is a family of variant sub-telomeric genes
named vir.129 On the basis of the sequence analysis, VIR pro-
teins are classified into different groups, which have been found
to have different subcellular localizations and functions.130 To
study the cellular trafficking and adhesive functions of VIR pro-
teins, they have been transfected into a poorly cytoadhesive
P. falciparum strain (3D7), permitting gain of function studies.
Two of three transfected VIR proteins were transported to the
IE surface and one conferred ICAM1 binding activity.131
Whether cytoadhesion has a role in organ-specific disease com-
plications is currently being investigated. There are few autopsy
findings from polymerase chain reaction–confirmed P. vivax
mono-infections. In one postmortem series from Brazil, ARDS
and pulmonary edemawas associated with accumulation of neu-
trophils in the interalveolar space, and scattered P. vivax IEs
were present inside the pulmonary capillaries.132 A single
autopsy performed in India showedmonocyte infiltrates in alve-
olar capillaries.133 It has been postulated thatP. vivax sequestra-
tion in pulmonary microvessels may trigger the inflammatory
influx,134 butmore work is needed to prove this hypothesis.
Parasite invasion pathways and vivax malaria severity. In
contrast to the deadly P. falciparum, which is able to invade
RBCs of all age, it has been suggested that the lack of fatalities
from P. vivax malaria is related to its unique restriction to inva-
sion and growth in reticulocytes. TheDuffy blood group antigen
on RBCs has a key role in invasion.118 This protein is recog-
nized by the P. vivaxDuffy binding protein (DBP),135 a leading
vivax vaccine candidate. Although the identification of Duffy-
dependent and Duffy-independent strains in Madagascar136
indicates that P. vivax can use alternative invasion pathways, it
is unknown how extensively Duffy-independent strains are dis-
tributed throughout the world. In addition, a single amino acid
polymorphism in the Duffy antigen Fy(a)/Fy(b) affects P. vivax
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invasion efficiency and the risk of clinical vivax in Brazil,137 but
the effect of this polymorphism has not been examined in other
parts of the world.
Despite the strong preference of P. vivax for reticulocytes,
there is still a relatively poor understanding of why P. vivax is
unable to invade normocytes or of the potential role of alter-
native invasion pathways in disease severity. A reticulocyte-
binding protein complex was identified (PvRBP-1 and
PvRBP-2), which plays a key role in reticulocyte binding and
invasion.138 A related protein family was subsequently dis-
covered in P. falciparum and named reticulocyte homology
or RBL proteins. Plasmodium vivax genome sequences indi-
cate the presence of numerous RBL paralogs,22 and intrigu-
ingly an additional DBP paralog,139 which might contribute
to different modes of invasion, immune evasion, and patho-
genesis. Within the India ICEMR, P. vivax in vitro invasion
assays are being conducted to characterize the role of inva-
sion pathways in disease severity.
CROSS-ICEMR COMPARISON OF RESEARCH
ACTIVITIES RELATED TO SEVERE MALARIA
The ICEMR program covers a wide range of malaria trans-
mission intensities for P. falciparum and P. vivax. Within the
ICEMR program, nine ICEMRs based in south Asia, India,
east and southern Africa, Amazonia, and southwest Pacific are
collecting descriptive data on the characteristics and outcomes
of patients admitted with severe malaria (Table 2). This broad
approach can provide a better understanding of the relationship
between severe malaria outcomes across the endemicity spec-
trum and may lend itself to meta-analysis to understand risk
factors for incidence of severe disease. In addition, individual
ICEMRs are investigating the role of prompt and effective
therapies on minimizing severe malaria outcomes in African
children and assessing the clinical profile and their association
with the parasite and host immunological status and the role
of nutritional factors and helminth coinfections in complicated
malaria cases in Colombia (Table 2).
CONCLUSIONS
Although the pathophysiology of CM is complex, pediatric
autopsy studies have demonstrated twomajor patterns: cerebral
microvessels with sequestered IEs alone (CM1) and cerebral
microvessels with IE sequestration plus evidence of endothelial
dysfunction and activation of coagulation (CM2). Ring hemor-
rhages and cerebral thrombosis are also described in a pro-
portion of adult cases, but whether there is an equivalent
CM1/CM2 dichotomy in adults is unclear. Neuroimaging stud-
ies have highlighted an important role for brain swelling in
pediatric CM, which is less commonly observed in adult CM.
A recent focus has been the microvascular interactions
between P. falciparum IEs and cerebral endothelial cells, and
how these binding interactions may contribute to disease pre-
sentation. Furthermore, because of the inaccessibility of cere-
bral microvessels, dermal biopsies provide a noninvasive
approach to profile the endothelial reactivity of patients with
severe or non-severe malaria complications. It has been postu-
lated that EPCR-binding parasites associated with severe
pediatric malaria may impair the protein C pathway in cerebral
microvessels and thereby directly contribute to coagulopathy
and endothelial barrier disruption. However, further work is
needed to understand to what extent parasite adhesion or endo-
thelial phenotypes may contribute to the pathophysiological
differences between CM1, CM2, and adult CM.
By comparison to P. falciparum, the lower lethality of P.
vivax may relate to invasion and growth in reticulocytes and
lower cytoadhesive properties. Nevertheless, despite its benign
reputation, there has been a surge in reports on severe vivax
malaria and a growing appreciation that P. vivax is not harm-
less. Recent studies in Peru suggest that severe vivax can occur
in monoendemic malaria regions.140 Although highly restricted
to reticuloctyes, genome projects have revealed a large expan-
sion of invasion ligand gene families in P. vivax. Thus, it will be
important to investigate if invasion pathways influence vivax
disease severity. Within the ICEMR program, current research
efforts are focused on understanding disease mechanisms, as
an important prerequisite to developing new tools to diagnose
and treat severe malaria.
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